Recent studies have demonstrated recurrent activating mutations involving the classical
MAPK and PI3K signaling pathways in a large proportion of histiocytic neoplasms, such as …

Histiocytic sarcoma is a rare malignant neoplasm that may occur de novo or in the context of
a previous hematologic malignancy or mediastinal germ cell tumor. Here, we performed …

Histiocytic neoplasms are clonal, hematopoietic disorders characterized by an accumulation
of abnormal, monocyte-derived dendritic cells or macrophages in Langerhans cell …

Histiocytic sarcoma, a rare malignant neoplasm showing morphologic and
immunophenotypic features of histiocytes, is characterized typically by extranodal …

Histiocytic sarcoma is a rare malignant neoplasm of presumed hematopoietic origin showing
morphologic and immunophenotypic evidence of histiocytic differentiation. Somatic mutation …

Langerhans cell histiocytosis (LCH) has a mostly favorable outcome, whereas Langerhans
cell sarcoma (LCS) is an aggressive tumor. It is still unclear whether any specific molecular …

Histiocytic sarcoma and tumors with dendritic cell differentiation (HDT) are uncommon
neoplasms often with an aggressive clinical course that may occur in association with …

Histiocytic sarcoma in humans is an aggressive orphan disease with a poor prognosis as
treatment options are limited. Dogs are the only species that spontaneously develops …

The bone marrow is a preferential site for both reactive and neoplastic histiocytic
proliferations. The differential diagnosis ranges from reactive histiocyte hyperplasia in …

Genomic analyses over the last 6 years have identified targetable kinase alterations in
BRAF V600E-wildtype histiocytic neoplasms. However, despite this progress, the molecular …